Illumina R&D increased by 0.4% to $240.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.8%, from $252.00M to $240.00M. Over 4 years (FY 2021 to FY 2025), R&D shows a downward trend with a -5.0% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $202.00M | $436.00M | $350.00M | $323.00M | $327.00M | $325.00M | $346.00M | $341.00M | $358.00M | $315.00M | $341.00M | $339.00M | $325.00M | $253.00M | $256.00M | $252.00M | $247.00M | $229.00M | $239.00M | $240.00M |
| QoQ Change | — | +115.8% | -19.7% | -7.7% | +1.2% | -0.6% | +6.5% | -1.4% | +5.0% | -12.0% | +8.3% | -0.6% | -4.1% | -22.2% | +1.2% | -1.6% | -2.0% | -7.3% | +4.4% | +0.4% |
| YoY Change | — | — | — | — | +61.9% | -25.5% | -1.1% | +5.6% | +9.5% | -3.1% | -1.4% | -0.6% | -9.2% | -19.7% | -24.9% | -25.7% | -24.0% | -9.5% | -6.6% | -4.8% |
| Segment | Q1 '25 |
|---|---|
| Core Illumina | $252.00M |
| Total | $252.00M |